Tissue Therapies Limited  

(Public, ASX:TIS)   Watch this stock  
Find more results for TIS
+0.005 (4.76%)
Delayed:   10:29AM GMT+11
ASX data delayed by 20 mins - Disclaimer
Currency in AUD
Range 0.10 - 0.11
52 week 0.10 - 0.47
Open 0.10
Vol / Avg. 396,510.00/805,672.00
Mkt cap 34.88M
P/E     -
Div/yield     -
EPS -0.03
Shares 280.92M
Beta     -
Inst. own     -

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -6329.02% -2981.44%
Operating margin -6529.39% -3026.25%
EBITD margin - -2989.80%
Return on average assets -62.54% -39.45%
Return on average equity -69.64% -44.31%
CDP Score - -


L 19 179 Turbot St
+61-7-33343900 (Phone)
+61-7-33343999 (Fax)

Website links


Tissue Therapies Limited is an Australia-based biomedical technology company which develops and manufactures proteins for healing wounds. The Company provides effective treatments for acute and chronic wound, including chronic skin ulcers and burns. The company also provides treatments for psoriasis, scar prevention and various cancers including those of the breast, colon and prostate. VitroGro ECM, a product of Tissue Therapies, is a solution of synthetic protein that promotes healing and reduces pain in chronic wounds. The product is applied to the surface of a prepared wound and the liquid formulation allows the product to cover the irregular shape of the wound. Tissue Therapies Europe Limited a wholly owned subsidiary which is set up to provide administration support to Tissue Therapies Limited.

Officers and directors

Steven J. Mercer Chief Executive Officer, Managing Director, Executive Director
Drummond McKenzie Chief Financial Officer, Company Secretary
Zee Upton Chief Scientific Officer
Roger Brian Clarke Non-Executive Chairman of the Board
Melvyn John Bridges Non-Executive Director
Ross Iain Gladstone Non-Executive Director
Cherrell Hirst Non-Executive Director
Timothy Richard Hughes Non-Executive Director